With Coherus BioSciences gearing up to exit the biosimilars space altogether – having late last year struck a deal to divest its Udenyca (pegfilgrastim-cbqv) franchise to Intas in a transaction worth more than half a billion dollars – the firm has reported a rise of nearly two-thirds in Udenyca sales in 2024, while at the same time setting out plans for “organizational streamlining” and the loss of around 30% of its 225 employees as it moves ahead to focus on innovative immuno-oncology products.
Udenyca sales were up by 62% to $206m in 2024, “primarily due to increased market share,” offset by a “change in Udenyca segment mix” and the impact of a